Navigation Links
Sosei Announces Initiation of Phase I Study for SO-1105
Date:3/7/2012

TOKYO, March 8, 2012 /PRNewswire/ --

Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announces that its wholly owned Japanese subsidiary, Sosei Co., Ltd., has initiated a Japanese Phase I trial for SO-1105 for the treatment of oropharyngeal candidiasis. SO-1105 was originally developed by a French pharmaceutical company, BioAlliance Pharma, which received its first marketing authorization for SO-1105 in France in October 2006. SO-1105 has since been registered in 26 European countries, in South Korea, and in the United States, under the trade names Loramyc®/Oravig®.

The clinical study will be conducted in a single study centre in Japan, and is designed to evaluate the pharmacokinetics and safety of SO-1105 in healthy Japanese adults.

SO-1105 is an antifungal agent, administered as a muco-adhesive buccal tablet for the treatment of oropharyngeal candidiasis in immunocompromised patients. SO-1105 has the potential to become the first long-acting, sustained-release treatment in tablet form for oropharyngeal candidiasis in Japan that could enhance patients' compliance and quality of life.

Shinichi Tamura, CEO of Sosei Group Corporation, commented: "This is an important step forward in development of SO-1105. We will continue with our efforts to bring SO-1105 to the Japanese market, as it has the potential to provide meaningful benefits to OPC patients compared to existing treatments."

Notes for Editors:

About Oropharyngeal Candidiasis

Fungal infections of the oral mucosa are most frequently caused by Candida species, with C. albicans being the most common species associated with such infections. Oropharyngeal candidiasis is commonly found in immuno-compromised patients, including HIV and cancer patients, and in other chronic disease states such as diabetes. For instance, oropharyngeal candidiasis is the most frequently occurring infection in head and neck cancer patients undergoing radiation therapy. The clinical presentation of oropharyngeal candidiasis is variable with symptoms including soreness, burning, and/or altered taste. The signs of clinical candidiasis usually include white pseudomembraneous plaques and patches (thrush), erythematous lesions or occasionally angular cheilitis. Left untreated, the condition may progress to involve the esophagus or to more serious systemic complications.

About Sosei

Sosei is an international biopharmaceutical company anchored in Japan with a global reach. It practises a reduced risk business model by acquiring compounds from, and bringing compounds into, Japan through exploitation of its unique position within global markets.

For further information about Sosei, please visit http://www.sosei.com.

About BioAlliance Pharma

Dedicated to cancer and supportive care - cancer related pathologies, chemotherapy and radiotherapy-induced complications and opportunistic infections in immunocompromised patients - BioAlliance conceives and develops innovative products, especially in the hospital setting and for orphan or rare diseases.

For more information, visit the BioAlliance Pharma web site at http://www.bioalliancepharma.com.



'/>"/>
SOURCE Sosei Group Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sosei to Receive Grant from NEDOs FY2011 Innovation Promotion Programme for Development of Innovative Ophthalmic Solutions
2. Sosei Signs Definitive Distribution Agreement With ASKA for Commercialisation of SOH-075 (NorLevo(R))
3. Sosei Assigns AD 923 Assets to Pharmasol
4. Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237
5. Sosei Confirms the Safety of SD118 in Two Phase I Trials
6. Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting
7. Sosei Announces Completion of Phase III Trial for NorLevo(R)
8. Prime Therapeutics Announces CareCentered Contract™ with EMD Serono, Inc. for MS Drug Rebif®
9. ThermoGenesis Announces Webcast of Presentation at Roth Capital Conference
10. Patented Protection Against Counterfeit Pharmaceuticals and Retail Fraud. ICAP Patent Brokerage Announces for Auction a Patented System for Verification of Purchase and Product Legality
11. CVS Caremark Corporation Announces Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... YORK , May 25, 2016 ... Market Size, Share, Development, Growth and Demand Forecast to ... Syringe, Insulin Pump and Others)" published by P&S Market ... at $9,998.3 million in 2015, and it is expected ... Based on type, the insulin pump segment is expected ...
(Date:5/25/2016)... Inivata, a global clinical ... tumour DNA (ctDNA) analysis to improve personalised healthcare ... Clive Morris as Chief Medical Officer. ... development programme, scientific collaborations, and through to commercialisation ... in clinical outcomes for patients. Clive ...
(Date:5/24/2016)...   , Study met ... and superiority in , Excellent plus ... of the ascending colon   , ... B.V. today announced new positive data from the phase III MORA ... standard 2 litre PEG with ascorbate. The study met both primary ...
Breaking Medicine Technology:
(Date:5/26/2016)... Georgia (PRWEB) , ... May 26, 2016 , ... ... certificate in intellectual property (IP) to its specialty academic programs. , Answering to ... the college’s existing certificate programs in health law, and environmental and land use ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... a significant negative impact on long-term patient survival, reports a team of UPMC ... online this week in the Journal of Thoracic and Cardiovascular Surgery, provide critical ...
(Date:5/26/2016)... ... May 26, 2016 , ... Dr. James Maisel will present ... Island Chapter on June 4, 2016, 1:30-3:30 pm at the Farmingdale Public Library. ... Retina Group of New York , is a Board Certified ophthalmologist who completed ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... supply chain solutions, today announced the organization has earned its ISO 13485 certification, ... and is compliant with all rules and policies associated with ISO quality standard ...
(Date:5/26/2016)... ... 26, 2016 , ... Nike Yoga Camps at East West ... arts & crafts, discussions, and games all geared towards enhancing your child’s physical ... backgrounds in kids’ yoga, collegiate sport yoga instruction, and global yoga training. Nike ...
Breaking Medicine News(10 mins):